ArticleCurrent issues in molecular biology2025
Construction and Evaluation of a HCoV-OC43 S2 Subunit Vaccine Fused with Nasal Immuno-Inducible Sequence Against Coronavirus Infection.
Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Editorial for Special Issue "Recombinant Proteins for Molecular Biology Research: Technologies and Applications".Current issues in molecular biology · 2026Article
- Current Status and Challenges of Vaccine Development for Seasonal Human Coronaviruses.Vaccines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A partial sequence of an human coronavirus (HCoV)-OC43 S2 subunit that cross-reacts with the S2 subunit of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was fused with a nasal immuno-inducible sequence (NAIS), and the resulting complex was used for intranasal immunization of rabbits. Crude serum from rabbits immunized with three doses showed an IgG titer > 1000 against the S2 subunits of HCoV-OC43 and SARS-CoV-2 and inhibited OC43 viral replication as a neutralizing antibody in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.